AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.
AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.
<iframe src="https://hindustansphere.com/embed/cluster/1170e20eaa46d6ac03feff7290d019cd85a07e3a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Summit stock surges on $2 billion AstraZeneca investment"></iframe>
